TESARO, Inc. (NASDAQ:TSRO) is set to announce its earnings results after the market closes on Wednesday, November 1st. Analysts expect the company to announce earnings of ($1.16) per share for the quarter.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm had revenue of $29.50 million during the quarter, compared to analysts’ expectations of $18.61 million. During the same quarter in the previous year, the company posted ($1.28) earnings per share. TESARO’s revenue for the quarter was down 17.6% compared to the same quarter last year. On average, analysts expect TESARO to post $-8.9 EPS for the current fiscal year and $-5.11 EPS for the next fiscal year.

TESARO, Inc. (NASDAQ TSRO) opened at 112.39 on Wednesday. The stock’s market capitalization is $6.09 billion. The stock has a 50 day moving average price of $120.07 and a 200-day moving average price of $132.14. TESARO, Inc. has a 12-month low of $106.64 and a 12-month high of $192.94.

Several analysts recently weighed in on the company. Gabelli assumed coverage on TESARO in a research note on Friday, July 7th. They issued a “buy” rating and a $175.00 price objective on the stock. ValuEngine upgraded TESARO from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Credit Suisse Group set a $198.00 target price on TESARO and gave the stock a “buy” rating in a report on Wednesday, July 19th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $199.00 target price on shares of TESARO in a report on Sunday, September 10th. Finally, BidaskClub upgraded TESARO from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. TESARO currently has an average rating of “Hold” and an average price target of $166.10.

In related news, VP Grant C. Bogle sold 14,167 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $135.00, for a total transaction of $1,912,545.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Edward C. English sold 10,862 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total value of $1,465,501.04. Following the transaction, the vice president now directly owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,692 shares of company stock valued at $4,628,976. 34.60% of the stock is owned by corporate insiders.

WARNING: “TESARO, Inc. (TSRO) Scheduled to Post Quarterly Earnings on Wednesday” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/25/tesaro-inc-tsro-scheduled-to-post-quarterly-earnings-on-wednesday.html.


TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Earnings History for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.